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Abstract
Evidence indicates that a diet rich in omega (W)-6
polyunsaturated fatty acids (PUFAs) [e.g., linoleic acid
(LA)] increases prostate cancer (PCa) risk, whereas a
diet rich in W-3 decreases risk. Precisely how these
PUFAs affect disease development remains unclear.
So we examined the roles that PUFAs play in PCa, and
we determined if increased W-3 consumption can im-
pede tumor growth. We previously demonstrated
an increased expression of an W-6 LA-metabolizing
enzyme, 15-lipoxygenase-1 (15-LO-1, ALOX15), in pros-
tate tumor tissue compared with normal adjacent pros-
tate tissue, and that elevated 15-LO-1 activity in PCa
cells has a protumorigenic effect. A PCa cell line, Los
Angeles Prostate Cancer-4 (LAPC-4), expresses pros-
tate-specific antigen (PSA) as well an active 15-LO-1
enzyme. Therefore, to study whether or not the pro-
tumorigenic role of 15-LO-1 and dietary W-6 LA can be
modulated by altering W-3 levels through diet, we
surgically removed tumors caused by LAPC-4 cells
(mouse model to simulate radical prostatectomy). Mice
were then randomly divided into three different diet
groups—namely, high W-6 LA, high W-3 stearidonic
acid (SDA), and no fat—and examined the effects of
W-6 and W-3 fatty acids in diet on LAPC-4 tumor re-
currence by monitoring for PSA. Mice in these diet
groups were monitored for food consumption, body
weight, and serum PSA indicative of the presence of
LAPC-4 cells. Fatty acid methyl esters from erythrocyte
membranes were examined for W-6 and W-3 levels to re-
flect long-term dietary intake. Our results provide evi-
dence that prostate tumors can be modulated by the
manipulation of W-6:W-3 ratios through diet and that
the W-3 fatty acid SDA [precursor of eicosapentaenoic
acid (EPA)] promotes apoptosis and decreases pro-
liferation in cancer cells, causing decreased PSA dou-
bling time, compared to W-6 LA fatty acid, likely by
competing with the enzymes of LA and AA pathways,
namely, 15-LO-1 and cyclooxygenases (COXs). Thus,
EPA and DHA (major components of fish oil) could po-
tentially be promising dietary intervention agents in
PCa prevention aimed at 15-LO-1 and COX-2 as mo-
lecular targets. These observations also provide clues
as to its mechanisms of action.
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Introduction
Prostate cancer (PCa) remains one of the leading causes of
cancer deaths among men in the United States. Current ther-
apies for PCa include watchful waiting, radical prostatectomy,
hormonal therapy, and targeted radiation. Unfortunately, all
available therapies have associated risks and limitations,
and new therapeutic strategies are critically needed [1]. One
promising strategy involves the use of dietary intervention.
International incidence patterns and migrations studies, epide-
miological data, and animal and in vitro studies indicate that
consuming a diet rich in fat increases the risk for developing
PCa [2–7]. In a mouse xenograft model for PCa, an isocaloric
low-fat diet slowed prostate tumor growth, further corroborating
a role for fat in PCa development [8,9]. Dietary fat includes
omega (N) 3 and N-6 polyunsaturated fatty acids (PUFAs), both
of which play important roles in many human biologic process-
es. As humans cannot synthesize N-3 and N-6 PUFAs, they are
considered essential fatty acids. Although all mammalian cells
can interconvert PUFAs within each series by elongation, de-
saturation, and retroconversion, the two series are not inter-
changeable due to lack of the Fat-1 gene [10], which encodes
N-3 desaturase enzyme [11,12].
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Linoleic acid (LA; 18:2N-6) represents an N-6 PUFA com-
monly found in high-fat Western diets [13]. Terrestrial plants
synthesize LA and, once ingested by mammals, LA is either
metabolized to 13-(S)-hydroxyoctadecadienoic acid [13-
(S)-HODE] or converted further to arachidonic acid (AA;
20:4N-6). Three fatty acids, found primarily in fish oils, com-
prise the N-3 family: alpha linolenic acid (ALA or a-LNA;
18:3N-3), eicosapentaenoic acid (EPA; 20:5N-3), and doco-
sahexaenoic acid (DHA; 22:6N-3). ALA, synthesized by cold
water vegetation, is converted by fish to EPA and DHA. Of
note, through the same series of enzymes used to convert
LA to AA, humans can synthesize EPA and DHA from in-
gested ALA. The conversion of dietary ALA to EPA and DHA
is also dependent on the dietary N-6:N-3 ratio [13]. Impor-
tantly, US diets provide excessive LA [14], which competes
with ALA for desaturase and elongase enzymes, impeding
the formation of EPA and DHA. Studies have suggested that
the high incidence of PCa in Americans may, in part, result
from an imbalance in the ratio of N-3 to N-6 fatty acids be-
cause the typical American diet is low in N-3 and high in N-6.
The negative effects of fatty acids may be direct or in-
direct [15–21], and the preponderance of evidence indicates
that N-3 and N-6 fatty acids modulate PCa tumorigenesis.
Yet, how these fatty acids affect disease development re-
mains unclear. Work from our laboratory [17,18,22,23] and
that of others [24–28] suggest that metabolites of PUFAs di-
rectly impact PCaand that the ability to do sodepends on both
diet and metabolic enzyme expression. Recently, we demon-
strated an increased expression of an N-6 LA-metabolizing
enzyme, 15-lipoxygenase-1 (15-LO-1, ALOX15), in prostate
tumor tissue compared with normal adjacent tissue [17].
Although AA can also act as a substrate for 15-LO-1, yielding
the anti-inflammatory and proapoptotic metabolite 15-(S)-
hydroxyeicosatetraenoic acid (15-(S)-HETE), the 15-LO-1
enzyme greatly prefers LA. 15-LO-1 metabolizes LA to
13-(S)-HODE, which can regulate cell growth, differentiation,
and vascular homeostasis [17,18,24,29]. Although an in-
crease in 15-LO-1 in colon cancer has previously been
reported [30], this observation remains controversial [31].
TRansgenic Adenocarcinoma of Mouse Prostate (TRAMP)
mice fed a highly saturated fat diet developed higher prostate
tumor incidence compared with those fed a low-fat diet [32]
and displayed high 12/15-LO (orthologue of human 15-LO-1)
with PCa progression [33]. Human and mouse studies indi-
cate that a high-LA diet may be a major risk factor for
developing PCa, especially in those individuals with high
15-LO-1 concentrations in the prostate epithelium.
In addition, AA also acts as a substrate for cyclooxyge-
nases (COX) 1 and 2 [34]. Most tissues constitutively ex-
press low protein levels of COX-1 and no COX-2. Growth
factors or inflammatory agents rapidly induce COX-2 expres-
sion in prostate [35], and studies show overexpression of
COX-2 in PCa [36,37]. COX-2 overexpression, leading to the
production of proinflammatory prostaglandins (e.g., PGE2),
possibly contributes to PCa pathobiology. Recently, a study
has shown that the combination of DHA and celecoxib
(a COX-2–specific inhibitor) prevents PCa cell growth
in vitro [38]. This inhibition of disease development likely
results, in part, from the ability of the N-3 PUFA EPA to suc-
cessfully compete with LA and AA for 15-LO-1 and COX-2,
respectively. 15-LO-1 metabolizes EPA to 15-hydroxyeico-
sapentaenoic acid (15-HEPE) [39], a metabolite shown to
have antitumorigenic properties, whereas COX-2 metabo-
lizes EPA to the anti-inflammatory and antitumorigenic pros-
taglandin PGE3 [40,41]. The N-3 PUFA EPA also serves as
a substrate for 15-LO-1 and COX-2, but the metabolism of
EPA by these enzymes results in the formation of antitumori-
genic products. Therefore, N-3 fatty acids may not only
decrease the production of protumorigenic metabolites de-
rived from the N-6 fatty acid pathway, but may also result
in increased production of antitumorigenic metabolites.
Based on these studies, we hypothesized that a diet rich
in N-6 PUFAs would cause rapid prostate tumor progres-
sion through the 15-LO-1 and COX metabolic pathways,
whereas increased consumption of N-3 PUFAs would an-
tagonize this effect. Our study suggests two mechanisms for
slowing PCa progression: 1) EPA and LA both compete as
substrates for the enzyme 15-LO-1, which may result in a de-
crease in the protumorigenic metabolite of LA, 13-(S)-HODE,
and an increase in the antitumorigenic metabolite of EPA, 15-
HEPE; and 2) EPA and AA both compete as substrates for
the enzyme COX-2, which may result in a decrease in the
proinflammatory metabolite of AA, PGE2, and an increase in
the anti-inflammatory metabolite of EPA, PGE3. Thus, EPA
alone or EPA-derived fatty acids such as DHA could be pro-
mising dietary intervention agents in PCa aimed at 15-LO-1
and COX-2 as molecular targets.
Materials and Methods
Cell Culture
Los Angeles Prostate Cancer-4 (LAPC-4) PCa cells were
kindly provided by Dr. Robert Reiter (University of California-
Los Angeles, Los Angeles, CA) and maintained in phenol
red– free Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Carlsbad, CA) containing 5% heat-inactivated
fetal calf serum (Sigma, St. Louis, MO) with streptomycin–
penicillin antibiotics [designated DMEM/fetal bovine serum
(FBS)] in a 5% CO2 incubator at 37jC. The PC3-15LOS
(15-LO-1–overexpressing) PCa cells were grown in RPMI/
FBS medium containing 50 mg/ml Zeocin (Invitrogen).
RNA Isolation and Real-Time Reverse Transcriptase
Polymerase Chain Reaction (RT-PCR) Analysis
Total RNA was isolated using RNeasy kit (Qiagen, Inc.,
Valencia, CA), and its concentration was determined using
RiboGreen fluorescent dye (Molecular Probes, Inc., Eugene,
OR) with VersaFluor Fluorometer System (BioRad, Hercules,
CA). The quality and integrity of total RNA were assessed
on 1% formaldehyde agarose gels. First-strand cDNA was
synthesized using 1 mg of total RNA (DNase-treated) in a
20-ml RT reaction mixture. A 120-bp region of b-actin using
primers 5V-CCTGGCACCCAGCACAAT-3V and 5V-GCCGAT-
CCACACGGAGTACT-3V and a 140-bp region of 15-LO-1
using primers 15-LO-1 5V-CCAACCACCAAGGATGCAA-3V
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and 5V-GGAGAGAAGCCTGGTGGAAGT-3V were amplified.
Separately, PCR-amplified cDNA products were also electro-
phoresed in a 2% agarose gel. In parallel, all real-time PCR
reactions were performed in a 25-ml mixture containing 1/20
vol of cDNA preparation (1 ml), 1 SYBR Green buffer (PE
Applied Biosystems, Foster City, CA), 4 mMMgCl2, 0.2 mMof
each primer (b-actin and 15-LO-1), 0.2 mM deoxynucleoside
triphosphate mix, and 0.025 U of AmpliTaq Gold thermo-
stable DNA polymerase (Applied Biosystems). Real-time
quantitations were performed using iQ5 Real-Time PCR De-
tection System (BioRad). Fluorescence threshold value was
calculated using system software. Optimization experiments
showed that PCR for b-actin in triplicate was highly reproduc-
ible with a low intra-assay coefficient of variation (0.5%).
Cell Proliferation and Viability Analyses
LAPC-4 cells (5000 cells/well) were plated in each well of
96-well plates (Costar Cat. No. 3595) in 100 ml of DMEM/FBS.
Twenty-four hours after plating, cells were further grown in
serum-free medium containing appropriate concentrations of
eicosanoids and/or fatty acids in 0.1% ethanol (experimental)
vs 0.1% ethanol in PBS only (control; day 0) and 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT)
assays (ATCC, Manassas, VA) performed on cells grown for
96 hours. The concentrations of EPA, DHA, and 15-HEPE
were as described in the text and figure legends. At indicated
time periods, the medium was aspirated from the wells, and
200 ml of MTT reagent (1 mg/ml) was added to each well. The
cells were then incubated for 1 hour at 37jC and lysed by
the addition of 200 ml of isoamyl alcohol and by shaking for
20 minutes. A 200-ml aliquot of each sample was then trans-
ferred to 96-well plates and read in an enzyme-linked immu-
nosorbent assay reader at 570 to 690 nm. The percent
increase or decrease (corrected absorbance) in cell prolifera-
tion is measured and reported as 100 OD at 570 nm. Dou-
bling times were calculated by solutions of the equations
derived by unweighed linear regression analysis of semi-
logarithmic plots of the formazan data derived from the MTT
assay. To examine the dose response of EPA, DHA, EPA +
DHA, and 15-HEPE on growth, concentrations ranging from
10 to 300 mM were added in serum-free medium on day 0
and MTT assay was performed after 96 hours of incubation.
LAPC-4 cells were harvested, and survivalwas estimated from
those that excluded 0.2% trypan blue. Total and viable cell
contents were determined by counting in a hemocytometer.
15-LO-1 and COX Enzyme Activities in LAPC-4 Cells
To establish that 15-LO-1 and COX-2 enzymes are active
in LAPC-4 cells, cell homogenates (total protein, 800 mg) from
LAPC-4 cells were incubated with 25 mM [1-14C]AA or
[1-14C]LA (1  106 cpm; 15 nmol) in ethanol (2.5% of final
volume) in the presence or absence of stearidonic acid
(SDA) (10 mM) or EPA (10 mM) at 30jC for 15 minutes. The
SDA was an ethyl ester obtained from K.D. Pharma Bex-
bach GmbH (Am Kraftwerk 6, Bexbach D-66450, Germany).
The particular batch was 60% SDA and was verified by gas
chromatography analysis [stearic acid, 0.95; oleic acid, 3.7%;
LA, 2.2%; g-linolenic acid (GLA), 5.3%; ALA, 5.8%; EPA,
1.6%; DHA, <0.1%]. The reaction mixture (600 ml) contained
50 mM Tris–HCl (pH 7.4) and 5 mM CaCl2. In all buffers,
protease inhibitors were added just before use: phenylme-
thylsulfonyl fluoride and benzamidine at 1mMeach, aprotinin
and leupeptin at 10 mg/ml, and pepstatin A at 1 mg/ml. After
incubation, 0.3mg of sodium borohydridewas added, and the
mixture was kept on ice for 15minutes. This mixture was then
acidified with HCl (pH 3.0). Appropriate unlabeled eicosa-
noids were used as internal standards. The sample was ex-
tracted in 2ml of ethyl ether, the solvent was evaporated, and
the dried material was dissolved in 50 ml of methanol:water
(3:1) solvent. Reverse-phase high-performance liquid chro-
matography (HPLC) analyses were conducted with a C18
ultrasphere column (5 mm; 4.6  250 mm; Altex Scientific/
Beckman Instruments, Fullerton, CA) equippedwith aWaters
model 6000A pump and a Waters (Milford, MA) model 717
autosampler injector. Metabolite separation was achieved
using a 55% to 100% methanol stepwise gradient at 1.1 ml/
min. Eluted radioactivity was monitored using Flo-One/Beta
detector (Radiomatic Instruments, Tampa, FL) linked with an
IBM Pentium 4 computer for data processing. UV analysis
was also performed (for nonradioactive detection of SDA,
EPA, and 15-HEPE) by monitoring absorbance at 234 nm
with a Waters 486 detector. [1-14C]AA and [1-14C]LA (40–60
mCi/mmol) were from DuPont-New England Nuclear (Bos-
ton, MA). Unlabeled eicosanoids such as 13-hydroxyoctade-
cadienoic acid (13-HODE), 15-HETE, and 15-HEPE, and
prostaglandins such as PGE2 and PGE3 were from Cayman
Chemical (Ann Arbor, MI). All solvents were HPLC-grade and
were from Baker (Phillipsburg, NJ). 15-LO-1 and COX en-
zyme activities were expressed as percent conversion of
substrate(s) to product(s).
Enzyme Activity Calculation for Eicosanoid
Pathway Analysis
The activities of enzymes (Table 2) involved in fatty acid
biosynthesis were estimated as product-to-precursor ratios
of the percentages of individual fatty acids [42]. Estimated en-
zyme activities included those of elongase, calculated as
stearic acid (18:0):palmitic acid (16:0) ratio; D-5 desaturase,
calculated as the AA (20:4, N-6):dihomo-g-linolenic acid
(DGLA; 20:3, N-6) ratio; D-6 desaturase, calculated as the
DGLA (20:3, N-6):LA (18:2, N-6) ratio (assuming that D-6
desaturase, and not elongase, is rate-limiting); and D-9 de-
saturase, calculated as the oleic acid (18:1, N-9):stearic acid
(18:0, N-9) ratio.
Animal, Feeding Protocol, LAPC-4 Injection, and Mouse
Model to Simulate Radical Prostatectomy (MSRP)
Seventy-two athymic male BALB/C nude (nu/nu) mice
(6–8 weeks old) were obtained from Charles River (Wilming-
ton, MA) and started on a no-fat diet. The mice were housed
in single sterile animal cages to allow for the maintenance
of isocaloric intake between diet groups. Cages, bedding,
and water were autoclaved before use. Specially designed
feeding receptacles were placed in the cages so that food
intake could be carefully monitored. Sterile techniques
were used during the handling of cages, mice, and food.
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The Pittsburgh Animal Research Committee approved the
experiments, and animals were cared for in accordance with
institutional guidelines.
We used three different diets for our study: two diets were
isocaloric and contained the same percent fat whereas one
contained no fat (Table 3). These custom-made semipurified
diets were prepared and irradiated by Purina Test Diet, Inc.
(Richmond, IN). The high N-6 diet contained 15 wt.% saf-
flower oil (70% LA), which provided 10.5 wt.% LA in the
diet, whereas the high N-3 fat diet contained 15 wt.% SDA
oil (SDA, 60% a precursor of EPA). Thus, the SDA diet pro-
vided 9 wt.% SDA (see Table 3 for composition). Use of pure
EPA is cost-prohibitive; therefore, SDA, an immediate pre-
cursor of EPA, served as a legitimate substitute. Further-
more, because of concerns with mercury and polychlorinated
biphenyl contamination of fish and fish oils, which currently
provide the major sources of long-chain N-3 in the human
diet, land-based sources of functional N-3 fatty acids such as
SDA are currently being developed [43]. The caloric density
of each of the fat-containing diets was 4.4 kcal/g. Note that
the no-fat diet was not isocaloric to the fat diets because our
study does not evaluate the role of the no-fat diet but spe-
cifically examines the individual roles of PUFAs in PCa. All
the mice (n = 72) were kept on a no-fat diet for 2 weeks be-
fore the start of the experiment, so that tumor transplantation
and the outcome of this study would not be confounded by
variations in fatty acid levels from regular/normal diets.
The day the mice were injected with LAPC-4 cells was
counted as week 1. The mice were injected subcutaneously,
in duplicate, in the right and left lateral flanks with 1  106
LAPC-4 tumor cells in 0.1 ml of Matrigel (Collaborative Bio-
medical Products, Bedford, MA). After LAPC-4 cell implan-
tation, the mice (n = 72) continued on a no-fat diet for the
first 9 weeks. On week 9, the tumors from the mice were sur-
gically removed, skin was sutured, and mice were allowed
to recover overnight. The mice were then randomly assigned
(n = 24 per diet group) to LA, SDA, and no-fat diet groups
and continued feeding over a 15-week time period (end
point of the study). Throughout the experiment, mice were
weighed and tumors were examined weekly. When tumors
became palpable, tumor dimensions were measured using
a caliper. Tumor volumes were calculated using the formula:
length  width  height  0.5236 [22].
Serum and Tumor Studies
The animals were euthanized when they had met institu-
tional guidelines. Blood (100 ml) was collected from the dorsal
metatarsal saphenous vein, and the serum was separated
[44]. Serum was collected on weeks 1, 7, 9, 12, and 15, res-
pectively (Figure 4), and assayed for prostate-specific anti-
gen (PSA) using an enzyme-linked immunosorbent assay
(ELISA) specific for human serum PSA (Diagnostic Systems
Laboratories, Inc., Webster, TX).
Fatty Acid Composition from Erythrocyte Membranes
and LAPC-4 Cells
Washed erythrocyte membranes (from serum-separated
samples) or LAPC-4 cells (1  106) were extracted with
chloroform/methanol and fatty acid methyl esters prepared
by BF3 transmethylation. Fatty acid methyl esters were ana-
lyzed by temperature-programmed microcapillary gas liquid
chromatography using an IDSP-2380 column (30 cm 
0.25 mm; Supelco, Supelco Park, PA) by reference to known
standards (NuCheck Prep, Elysian, MN). The fatty acids are
expressed as a percentage from total phospholipids mea-
sured (C14/C22). The relative amount of each fatty acid was
quantified by integrating the area under the peak and divid-
ing the result by the total area for all fatty acids. The total
percentage of long-chain PUFA with z20 carbon units (C20–
C22 PUFA), the sum of n3 PUFA (18:3 n3, 20:5 n3, 22:5
n3, and 22:6 n3), and the sum of n6 PUFA (18:2 n6,
20:3 n6, and 20:4 n6) were calculated from primary data.
The interassay coefficient of variation for determination of
different fatty acids by this method ranged between 2.6%
and 9.1%, reflecting the high reproducibility of the assay.
Assessment of 15-LO-1, Apoptotic Index, and Proliferation
Index by Immunohistochemistry
Sections of formalin-fixed paraffin-embedded LAPC-4
tumor tissues (5 mm) were tested for the presence of
15-LO-1 (1:1600), Ki-67, and caspase-3 (1:50), using an
avidin–biotin complex technique and steam heat– induced
antigen retrieval. Cells were defined as apoptotic if the
whole nuclear area of the cell was labeled positively for
caspase-3. Apoptotic bodies were defined as small positively
labeled globular bodies in the cytoplasm of tumor cells (singly
or in groups). To estimate apoptotic index (the percentage of
apoptotic events in a given area), apoptotic cells and bodies
were counted in 10 high-power fields, and this figure was di-
vided by the number of tumor cells in the same high-power
fields. We also estimated the apoptotic index by light micros-
copy using hematoxylin-stained slides from the same tumor
sections as those of caspase-3. The intensity of staining in
10 high-power fields was scored descriptively or semiquan-
titatively by a pathologist as: 1+, 0% to 25% positive cells;
2+, 25% to 50 % positive cells; 3+, 50% to 75% positive cells;
and z4+, 75% to 100% positive cells) in a blinded manner.
Proliferation was similarly examined, and the index was
estimated as total Ki-67– labeled cells/total cells counted.
Statistical Analyses
Statistical analyses (SAS ver 5.0) were performed by Stu-
dent’s t test or analysis of variance. Correlations between
outcome variables were computed using the Spearman
correlation coefficient. P V .05 was considered significant.
Data are expressed as mean ± standard deviation (SD).
Results
Effect of Eicosanoids and Fatty Acids on the Growth
of LAPC-4 Cells In Vitro
As shown in Figure 1, 15-LO-1 mRNA is expressed in
LAPC-4 cells as determined using a PC-3 cell line over-
expressing 15-LO-1 (PC3-15LOS) as standard. This obser-
vation was further confirmed by quantitative PCR analysis
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(data not shown). As shown in Figure 2, a dose-dependent
inhibition in growth (at 96 hours) from initially plated 1  106
(considered as 100% for growth assay) LAPC-4 cells was
observed when supplemented with EPA, DHA, EPA + DHA,
and 15-HEPE in a growth medium (replaced by fresh media
every 12 hours). The effective growth-inhibitory concentra-
tion of 15-HEPE, DHA, and EPA was 50 mM. Overall, the
inhibition was EPA + DHA > EPA > 15-HEPE > DHA, respec-
tively. The inhibition data also point to an important obser-
vation. No difference in cell numbers was observed on day 1
from those seeded on day 0, indicating that none of the
eicosanoids or fatty acids exerted any cytotoxicity effects.
Moreover, neither the N-3 EPA and DHA nor the eicosanoid
EPA causes toxicity at higher concentrations (i.e., from 100
to 300 mM). This dose-dependent inhibition was not observed
in the benign prostatic hyperplasia-1 cell line containing
undetectable levels of 15-LO-1 (data not shown). Similarly,
as shown in Figure 3, there was increase in the growth/pro-
liferation of LAPC-4 cells when supplemented with 100 mM
LA and AA in the growth medium (replaced by fresh media
every 12 hours), although LA showed a two-fold- to three-
fold-higher proliferation rate when compared with AA over a
96-hour time period. However, 50 mM EPA or DHA (alone or
in combination) caused inhibition in LAPC-4 growth when
added with either 100 mM LA or AA in the growth medium
over the same time period (i.e., 96 hours). This result sug-
gests that the inhibition of LAPC-4 cell growth by EPA and
DHA is caused by competition with LA and AA as substrates
for 15-LO-1 and/or COX enzyme.
15-LO-1 and COX Enzyme Activities in LAPC-4 Cells
To study whether N-3 EPA and SDA inhibited LAPC-4 cell
growth by substrate competition with LA and AA for 15-LO-1
and COX enzymes, we incubated these substrates (i.e., LA,
AA, SDA, LA + SDA, AA + SDA, EPA, LA + EPA, and AA +
EPA) with proteins extracted from untreated LAPC-4 cells
and analyzed for metabolites by HPLC analysis (Table 1).
No substrate incubations served as controls. The ability of
LAPC-4 cells to form 13-HODE from exogenous LA (the pre-
ferred substrate of 15-LO-1) and 15-HEPE from exogenous
EPA or SDA was used to confirm 15-LO-1 activity in the
LAPC-4 cells. Similarly, the formation of prostaglandins from
LA, AA, SDA, and EPA confirmed COX activity (Table 1). This
result also demonstrated the ability of the LAPC-4 cells to
convert LA to AA through the desaturase/elongase pathway
Figure 1. RT-PCR of 15-LO-1 and -actin expression in LAPC-4 and PC3-
15LOS cells (control).
Figure 2. PUFA modulation of LAPC-4 proliferation. Cells were propagated
on medium containing 10% FBS. Monolayers were harvested, and cells were
plated (5  103 cells/well and considered as 100% cells) in 96-well plates on a
medium either containing different concentrations (0–300 M) or lacking
(control) EPA (D-D), DHA (.-.), EPA + DHA (x-x), and 15-HEPE (5-5).
Viable cell content was determined by quantification of formazan production.
For clarity, SD error bars from the mean of quadruplicate wells (SD V 10% of
the mean) have been omitted.
Figure 3. Effect of LA (100 M; n-n), AA (100 M;D-D), LA + EPA (50 M;
.-.), LA + EPA + DHA (50 M; 5-5), AA + EPA (o-o), and AA + EPA +
DHA (x-x) on the growth of 5  103 cells/well LAPC-4 in vitro. The untreated
cells were used as control (q-q). Each point represents the mean ± SD of
triplicate determinations from two separate experiments. For clarity, SD error
bars from mean of triplicate wells (SD V 10% of the mean) have been
omitted. Values are half times for either population doubling (positive values)
or viable cell loss (negative values). Half times were obtained by the solution
of regression equations.
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(Tables 1 and 2). The absence or undetectable amount of
15-HETE indicated either a deficiency in 15-LO-2 enzyme or
poor 15-LO-1/AA metabolism. Note that, although 15-LO-1
can also convert AA to 15-(S)-HETE, AA remains to be a poor
substrate. Importantly, these results also suggest that the
N-3 fatty acids SDA and EPA did not inhibit either 15-LO-1
or COX activities. On addition of SDA or EPA to the protein
extracts containing LA, we observed an approximately
0.5-fold decrease in the formation of 13-HODE metabolite
(1.98 ± 0.11 vs 0.92 ± 0.06, P < .01; or 1.98 ± 0.11 vs 0.87 ±
0.03, P < .01). We did not observe a statistically significant
difference in the formation of 15-HEPE metabolite with SDA
alone versus LA + SDA and AA + SDA (P = .4). A similar ob-
servation (P = .07) was noted with EPA alone versus LA +
EPA and AA + EPA, although we observed a 1.5-fold in-
crease in the 15-HEPEmetabolite with EPA, suggesting that,
among EPA and SDA, EPA is the preferred substrate and
that both EPAandSDA competed equally with LA for 15-LO-1
enzyme activity. Lastly, we did not observe dramatic differ-
ences in prostaglandin formation. These observations pro-
vided evidence that N-3 EPA and SDA inhibited LAPC-4
cell growth by substrate competition with LA and AA for 15-
LO-1 and COX enzymes and are both comparable in their
actions. Although the levels of prostaglandins remained
significantly unaltered, we did not analyze the spectrum of
prostaglandins formed because it is reasonable to assume
that the composition of individual prostaglandins might very
well be different (e.g., a shift from PGE2 to PGE3,).
Estimated Enzyme Activities of the LA and AA Pathways
and Modulation by EPA in LAPC-4 Cells
To obtain additional evidence to support the hypothesis
of EPA modulation in tumorigenesis, we examined percent
unsaturated or percent saturated fatty acids in total phos-
pholipids for PUFA N-6:N-3 ratios and for the major enzymes
of the N-6 catabolic pathway (by estimating product-to-
precursor ratios of the percentages of individual fatty acids)
(namely, elongase, D-5-desaturase, and D-6-desaturase)
and the N-9 anabolic fatty acid pathway enzyme D-9 desatu-
rase in LAPC-4 cells grown in vitro with and without LA, AA,
or EPA (Table 2). There were no apparent differences ob-
served in either the percent unsaturated or the percent satu-
rated fatty acids in the total phospholipids, suggesting that
the cells maintained the membrane fluidity and functionality
of proteins in the membrane. As shown in Table 2, we ob-
served a 2.6-fold increase in N-6:N-3 ratio with LA, a 1.7-fold
increase with AA, and a 3.7-fold decrease with EPA, com-
pared to untreated control. Furthermore,EPAaddition caused
a 4.3-fold decrease in N-6:N-3 ratio when the cells were
grown in the presence of LA compared to only LA-treated
LAPC-4 cells. Similarly, we also observed a 4.3-fold decrease
in N-6:N-3 ratio in the presence of AA + EPA compared to
AA-treated LAPC-4 cells. In view of the assumed signifi-
cance of lipid metabolism in PCa in connection with enzymes
of the N-6 and N-3 metabolic pathways, the increased esti-
mated activity of D-6-desaturase enzyme in the LAPC-4 cells
treated with EPA alone or in the presence of LA or AA com-
pared to untreated control, LA-treated, or AA-treated LAPC-4
cells may be associated with accumulation of antiprolifera-
tive GLA and DGLA. Similarly, a reduced estimated D-5-
desaturase activity suggested that EPA may be inhibiting
D-5-desaturase enzyme activity, which can then further limit
the formation of DHA as well as cause accumulation of GLA
and DGLA. Interestingly, the estimated activity of the anabo-
lic N-9 monounsaturated fatty acid pathway enzyme D-9-
Table 1. Enzyme (15-LO-1 and COX) Activity Profiles of LA, AA, SDA, LA +
SDA, AA + SDA, EPA, LA + EPA, and AA + EPA Metabolite Products from
LAPC-4 Cells Are Measured as Described in the Materials and Methods
Section.
Substrates Products*
13-HODE 15-HETE 15-HEPE Total
prostaglandins
LA 1.98 ± 0.11 ND 0 6.15 ± 0.32
AA ND ND 0 9.23 ± 0.77
SDA ND ND 0.82 ± 0.04 4.74 ± 0.14
LA + SDA 0.92 ± 0.06 ND 0.76 ± 0.03 5.15 ± 0.12
AA + SDA ND ND 0.80 ± 0.01 7.90 ± 0.19
EPA ND ND 1.77 ± 0.05 5.34 ± 0.14
LA + EPA 0.87 ± 0.03 ND 1.21 ± 0.03 4.75 ± 0.12
AA + EPA ND ND 1.43 ± 0.01 7.61 ± 0.23
ND, not detectable.
*Percent conversion (products) data represent the mean ± SD of triplicate
determinations from two separate experiments.
Table 2. Phospholipid Analyses of Unsaturated and Saturated Fatty Acids, PUFA Ratios, and LA, AA, EPA, and DHA Compositions from Untreated Control Versus
LA (100 MM)– , AA (100 MM)– , EPA (50 MM)– , LA + EPA– , and AA + EPA–Treated LAPC-4 Cells.
Total Phospholipids N-6/N-3 Elongase D-5-Desaturase D-6-Desaturase D-9-Desaturase
% Unsaturated % Saturated
LAPC-4 Control 50.3 ± 1.3 40.6 ± 1.1 3.4 ± 0.6 118.0 ± 4.4 7.0 ± 0.4 3.6 ± 0.6 17.7 ± 0.4
LA* 51.4 ± 1.4 43.8 ± 1.4 9.1 ± 0.2 112.4 ± 5.4 15.4 ± 0.3 6.1 ± 1.4 7.8 ± 0.7
AA* 49.7 ± 0.9 45.9 ± 1.2 6.1 ± 0.1 123.9 ± 3.7 12.3 ± 0.7 7.0 ± 0.5 9.3 ± 0.5
LAPC-4 EPA* 50.1 ± 1.1 42.4 ± 1.4 0.9 ± 0.04 38.0 ± 1.3 0.5 ± 0.04 11.6 ± 2.6 28.4 ± 0.6
LA + EPA* 52.8 ± 1.2 39.8 ± 1.2 2.1 ± 0.4 33.6 ± 1.5 0.9 ± 0.05 16.9 ± 1.7 18.2 ± 0.4
AA + EPA* 49.0 ± 1.4 45.4 ± 1.5 1.4 ± 0.5 35.1 ± 1.7 0.6 ± 0.05 12.4 ± 2.1 20.1 ± 0.3
Fatty acid methyl esters were analyzed by temperature-programmed microcapillary gas liquid chromatography, as described in Materials and Methods section. The
activities of key enzymes involved in fatty acid biosynthesis were estimated as the product-to-precursor ratios of the percentages of individual fatty acids. The
estimated enzyme activities included those of elongase, calculated as the stearic acid (18:0):palmitic acid (16:0) ratio; D-5-desaturase, calculated as the AA (20:4,
N-6):dihomo-g-linolenic acid (20:3, N-6) ratio; D-6-desaturase, calculated as the dihomo-g-linolenic acid (20:3, N-6):LA (18:2, N-6) ratio (assuming that D-6-
desaturase, and not elongase, is rate-limiting); and D-9-desaturase, calculated as the oleic acid (18:1, N-9):stearic acid (18:0, N-9) ratio. Data represent the mean ±
SD of triplicate determinations from two separate experiments.
*Concentrations added: LA (100 MM), AA (100 MM), and EPA (50 MM).
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desaturase decreased with LA and AA supplemented in the
growth medium, but remained unaltered in the presence of
EPA, suggesting that EPAmay favor the conversion of stearic
acid (18:0, N-9) to oleic acid (18:1, N-9); this conversion is
otherwise inhibited by either LA and/or AA. These observa-
tions provide additional support for the role of EPA in slowing
PCa growth.
MSRP and the Effect of Isocaloric Diets on Mice Weight
and Tumor Development
To confirm the observed in vitro effects of N-3 fatty acids,
these experiments focused on the in vivo effects of N-6 and
N-3 diets on tumor formation and tumor characteristics using
the MSRP (Figure 4). This model relies on athymic mice in-
jected with a PCa cell line, LAPC-4, to induce prostate tumors
and tests the efficacy of EPA in slowing prostate tumor
progression and recurrence. LAPC-4 cells produce PSA,
possess a wild-type androgen receptor, and show features
of hormone-dependent growth and metastasis, thus closely
resembling proliferating (neoplastic) epithelial cells of a pros-
tate. We are aware that this mouse model may not be an
adequate model of clinical cancer, especially with regard
to metastasis. However, considering the ease of mimicking
radical prostatectomy by surgically removing the tumors
from mice and then randomly assigning to the different diet
groups, we were assured of an outcome on tumor recurrence
based specifically on different diets (Figure 4 and Table 3).
After LAPC-4 cell implantation, the mice (n = 72) continued
on a no-fat diet for the first 9 weeks (Figure 4). Note that only
LA and SDA diets (not the no-fat diet) were isocaloric.
The average kilocalories consumed during that time period
were 100 kcal/week (data not shown). The feeding method
used in the present study successfully maintained equivalent
mouse weights throughout the study, although isocaloric
intakes among the different diet groups varied, particularly
in LA diet– fed mice. Ten- to 20-kcal variations in isocaloric
intakes (SDA versus LA, and SDA versus no-fat) were not
statistically significant (data not shown). This was a critical
element, given that animal studies with consumption of a
calorie-dense diet are reported to promote weight gain and
prostate tumor growth, and caloric restriction results in de-
creased tumor growth. All mice developed tumors from
weeks 2 to 8 and plateaued on week 9; the average tumor
size grew four-fold (Figure 5). On week 9, the tumors from the
mice were surgically removed, the skin was sutured, and the
mice were allowed to recover overnight. The mice were then
randomly assigned (n = 24 per diet group) to LA, SDA, and
no-fat diet groups and monitored for PSA recurrence, if any.
Effect of Diet on PSA, Tumor Size, and Tumor Recurrence
To examine the effects of specific diets on tumor size
and recurrence after tumor removal, serum from mice was
collected on week 1 (PSA undetectable and data not shown),
weeks 7 and 9 (Figure 6A), and weeks 12 and 15 (Figure 6B),
and assayed using an ELISA specific for human serum PSA.
Figure 4. MSRP. Male athymic male BALB/C nude (nu/nu) mice (6–8 weeks old) fed for 9 weeks. LAPC-4 cells were injected subcutaneously on week 1, and
tumor growth was monitored for 9 weeks. On week 9, tumors were surgically removed and mice were randomly assigned to high x-6 LA, high x-3 SDA, and no-fat
diet groups and fed accordingly until the termination of the experiment on week 15. Serum PSA was measured on weeks 1, 7, 9, 12, and 15, respectively. Tumor
volume, food consumption, and mouse weight were measured every week.
Table 3. Composition of Isocaloric Diets.
Ingredient*,y No Fat SDA (N-3) LA (N-6)
Sucrose 35.0 35.0 35.0
Casein (vitamin-free) 21.0 21.0 21.0
RP mineral mix no. 10
(adds 1.29% fiber)
5.0 5.0 5.0
Powdered cellulose 3.0 3.0 3.0
RP vitamin mix
(adds 1.9% sucrose)
2.0 2.0 2.0
Choline chloride 0.2 0.2 0.2
DL-methionine 0.2 0.2 0.2
SDA 0.0 15.0 0.0
Safflower oil 0.0 0.0 15.0
Dextrin 33.6 18.6 18.6
Three synthetic diets [namely, no fat (nonisocaloric), high N-3 SDA, and high
N-6 LA] were designed with constant fat levels. The caloric density of each of
the fat-containing diets was 4.4 kcal/g.
*g Ingredient/100 g diet.
yValues supplied by the supplier.
118 Prostate Cancer Recurrence is Modulated by PUFA Kelavkar et al.
Neoplasia . Vol. 8, No. 2, 2006
We observed that the average PSA per tumor volume in
mice on week 9 vs week 7 was not significantly different
(Figure 6A; P = .2), suggesting that the PSA level in tumors of
no-fat diet– fed mice remains unaffected during that time
period. Next, we observed 5.34 ng/ml PSA in 4 of 24 (?16%
recurred) mice on week 12 in LA (high N-6) diet– fed mice
and 1.83 ng/ml PSA in 2 of 24 (?8.3% recurred) in SDA (high
N-3) diet–fed mice; neither tumor nor PSA was observed/
detected in the no-fat diet–fed group (Figure 6B). These ob-
servations suggested that, although no palpable tumors were
observed in either of the groups on week 12, rapid tumor re-
currence had occurred in LA diet– fed mice compared to the
SDA diet–fed mice. However, on week 15, palpable tumors
were detected. Although the number of mice with tumors and
those that were positive for PSA remained the same as in
week 12, strikingly, the size of the tumors in the SDA diet–
fed mice was eight-fold smaller in size compared with those
in the LA diet– fed mice, and the levels of PSA examined
corresponded to tumor size (70.15 ng/ml PSA in LA diet– fed
mice vs 8.50 ng/ml PSA in SDA diet–fed mice) accordingly
(Figure 6B). These results suggested that tumor recurrence
was 50% reduced in SDA diet–fed mice than in LA diet– fed
mice (from 16% to 8%). Although PSA velocity could not be
determined, interestingly, PSA doubling time decreased by
c1.5-fold in recurrent tumors of SDA diet–fed mice versus
LA diet– fed mice.
Effect of Diet on Total Red Blood Cell (RBC) Phospholipids
In order for the in vivo experiments to accurately assess
the effects of diet on PCa, the N-6:N-3 fatty acids ratios
normally found in individuals must be recapitulated in the
mice. We chose to examine whether the LA, SDA, and no-fat
diets modulated N-6:N-3 ratios by evaluating mouse RBC
phospholipids because RBCs are responsive to diet and ap-
pear to accurately reflect long-term dietary intake for many
of the fatty acids, particularly the n3 long-chain PUFA
[45,46]. Furthermore, the distribution of fatty acids in RBC
membranes has been validated as an accurate estimate of
the distribution of fatty acids in the diet [47–52]. An additional
theoretical advantage is that phospholipid fatty acids proba-
bly represent the most pertinent cell membrane component
in tissues (i.e., prostate), and there appears to be a contin-
uous exchange of dietary fats among various blood compart-
ments [46–49]. As shown in Figure 7, A and B, there were
statistically significant differences in the composition of LA,
EPA, and DHA in the RBC phospholipids measured (AA was
Figure 5. Average tumor volume per week in experimental mice. Average tumor volume (mm3; dotted line) per mouse was examined every week up to week 9
(before tumor resection) in the no-fat diet group (n = 72).
Figure 6. (A) Average PSA per tumor volume in the no-fat diet – fed mice on week 7 vs week 9 (n = 72). ***P = .2. (B) Number of mice showing tumor recurrence,
average tumor volume, and PSA, after tumor resection, in mice fed no-fat, high x-3 SDA, and high x-6 LA diets on week 12 vs week 15. NO, not observed.
*Estimated value.
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not statistically different) in N-6 LA and N-3–SDA diet groups
on weeks 12 and 15, respectively. Drastic differences were
not observed in the total LA, AA, EPA, and DHA composition
in phospholipids from reticulocytes harvested on week 12 vs
week 15. Similarly, the LA, AA, EPA, and DHA compositions
in tumor phospholipids on week 15 (from LA diet– and SDA
diet–fed mice) were comparable to those observed from re-
ticulocytes (data not shown). Furthermore, the N-6 (LA and
AA):N-3 (EPA and DHA) ratios were 17–20:1 in LA diet– fed,
1:1 in SDA diet–fed, and 5:1 in no-fat diet– fed mice, respec-
tively. These data suggest that the phospholipids in RBCs
are responsive to diet, represent phospholipids in tumor tis-
sues, and remain practically constant by week 12.
Effect of Diet on Proliferation and Apoptotic Indices
in Recurrent Tumors
To examine the in vivo effects of N-3 and N-6 fat diets on
the rate of tumor recurrence (slow versus fast tumor growth),
we next evaluated, by immunohistochemistry, proliferation
status (Ki-67) and apoptosis (Caspase-3) in tumors from
mice fed LA and SDA diets (n = 2). As depicted in Figures 8
and 9, although 15-LO-1 protein levels remained similar,
Ki-67 expression and the calculated percent proliferation
index increased in tumors from mice fed the N-6 diet
when compared to tumors from mice fed the N-3 SDA diet.
Furthermore, increased apoptosis was observed in tumors
of N-3 SDA diet–fed mice versus tumors from N-6 diet– fed
mice. These results suggest that, although differences in per-
cent proliferation index were observed in both diet groups,
N-3 EPA dramatically modulated the percent apoptotic index
in tumor cells (Figure 9).
Discussion
International incidence patterns and migrations studies, ep-
idemiological data, and animal and in vitro studies indicate
Figure 7. Composition of LA, AA, EPA, and DHA in erythrocyte phospholipids
(n = 3) from mice fed no-fat, high x-3 SDA, and high x-6 LA diets on (A) week
12 vs (B) week 15. Fatty acid methyl esters from erythrocytes were analyzed
by gas liquid chromatography, as described in Materials and Methods
section. The fatty acids are expressed as percentages of total phospholipids.
*P < .01, **P < .05, ***P = .2, ****P = .3.
Figure 8. Representative immunostaining (A–D) and hematoxylin and eosin (H&E) staining (E and F) of tumors from mice fed high x-3 SDA and high x-6 LA diets
on week 15 with polyclonal antibody for 15-LO-1 (brown), dual staining with Ki-67 (brown) as a proliferation marker, and caspase-3 (red; arrowheads) as an
apoptosis marker (40). x-3 SDA (A, C, and E) and x-3 SDA (B, D, and F). (A and B) 15-LO-1; (C and D) dual Ki-67/caspase-3; (E and F) H&E staining.
120 Prostate Cancer Recurrence is Modulated by PUFA Kelavkar et al.
Neoplasia . Vol. 8, No. 2, 2006
that consuming a diet rich in fat increases the risk for
developing PCa. For example, a wide variation in interna-
tional PCa mortality rates exists; rates are particularly high
in Northern Europe and North America, whereas they are
much lower in Japan and other Asian countries [2]. In con-
trast, the frequency of latent carcinoma of the prostate diag-
nosed at autopsy is as common in Japanese males as in
the male population of the United States, Canada, and UK
[3]. These findings implicate environmental variables, such
as diet, as a significant contributing factor. Indeed, immi-
grants from Poland and Japan, where the incidence of PCa
is low, exhibit a significant increase in the risk for developing
PCa after moving to the United States [4–7]. Shennen and
Bishop [5] reported a positive relationship between the
consumption of dietary fats, including PUFAs, and the de-
velopment of PCa in 32 countries. Moreover, regional con-
sumption of high-fat foods in the United States parallels that
of mortality from PCa [3–6]. Although all mammalian cells
can interconvert N-6 and N-3 PUFAs within each series by
elongation, desaturation, and retroconversion, the two series
are not interchangeable.
Our previous in vitro and in vivo studies demonstrating
the presence of N-6 LA-metabolizing enzyme 15-LO-1 at
higher levels in PCa compared to that in the normal epithe-
lium, and the correlation between expression and Gleason
grade suggested that 15-LO-1 is a key enzyme that contrib-
utes to the initiation and development of the neoplastic
phenotype in PCa [17,18,22,23]. Based on the current study
and other reports supporting our observations, we propose
a mechanistic approach as to how the metabolites of anti-
tumorigenic N-3 fatty acids can modulate the protumorigenic
N-6 LA andAA enzymatic pathways (Figure 10). An important
finding in the present study using the mouse xenograft model
mimicking prostatectomy for studying recurrence (biochemi-
cal failure) is that the N-3 diet– fed mice demonstrated slower
LAPC-4 tumor recurrence and PSA doubling time, relative to
mice fed an N-6 diet. This study attempts to clarify the roles
of N-3 fatty acids that promote apoptosis and decrease pro-
liferation in cancer cells likely by competing with the enzymes
of the LA and AA pathways (15-LO-1 and COX). Therefore,
the use of dietary N-3 PUFAs as agents for cancer prevention
can prove to be a valuable strategy in the fight against PCa
[53–62] and recurrence. Our observations confirmed that
LAPC-4 cells expressed active 15-LO-1 and COX enzymes
and that LA and AA fatty acids were pro-proliferative in their
actions in vitro. Amixture of DHA+EPAmimicking fish oil was
themost effective nontoxic in vitro growth inhibitor, compared
to EPA alone, toward LAPC-4 proliferation even in the pres-
ence of LA or AA. This result supports a previous observation
Figure 9. Assessment of (A) proliferation index and (B) apoptotic index in
recurrent tumors on week 15 from mice fed high x-3 SDA (n = 2) and high
x-6 LA diets (n = 2). Sections of formalin-fixed paraffin-embedded LAPC-4
tumor tissues were tested for the presence of 15-LO-1, Ki-67, and caspase-3.
Proliferation and apoptotic indices (%) were estimated as described in
Materials and Methods section.
Figure 10. Modulation of the enzymes of the LA and AA pathways by x-3 and x-6 fatty acids.
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on the effects of N-3 and N-6 fatty acids on the growth of PCa
cells [63] and provides explanations for the previously con-
ducted studies evaluating fish oils as well as flaxseeds in PCa
intervention trials that have yielded confounding results
(reviewed in Ref. [64]).
In addition to 15-LO-1, evidence also suggests that other
metabolic enzymes play important roles in PCa pathobiology.
AA obtained through diet or LA metabolic conversion is the
preferred substrate for 15-lipoxygenase-2 (15-LO-2). 15-LO-
2 converts AA to 15-(S)-HETE, a metabolite shown to both
enhance apoptosis and act as a negative cell cycle regula-
tor [65]. Furthermore, 15-(S)-HETE has anti-inflammatory
properties [66,67], and studies support an association be-
tween inflammation and PCa [68,69]. However, PCa tissue
or LAPC-4 cells (this study) express very little 15-LO-2 [70].
Similarly, AA also acts as a substrate for COX-2, leading to
the production of prostaglandins, such as PGE2, that have
proinflammatory effects and thus possibly contribute to PCa
pathobiology. Although the present study did not specifically
evaluate both COX-1 and COX-2 levels for prostaglandins
such as PGE2 versus PGE3, previous studies have demon-
strated overexpression of COX-2 [36,37] and an antitumori-
genic role of PGE3 in PCa [39]. Therefore, due to the
abundance of COX-2 in PCa tissues, it was reasonable to
assume that the vast majority of AA in LAPC-4 cells would
be converted to PGE2 if N-3 were low or absent.
Previous studies suggest that the high incidence of PCa
in Americans may, in part, result from an imbalance in the
N-3:N-6 PUFA ratio [3,4]. Ideally, the N-3:N-6 PUFA ratio in
the human body should be 1:4 to 1:1 [71]. The typical US diet
is low in N-3 and high in N-6, and many individuals contain 10
to 20 times more N-6 PUFAs than N-3 PUFAs [72–74]. Al-
though an increase in the N-6:N-3 ratio with LA and AA com-
pared to untreated control was evident, the addition of EPA
to LAPC-4 cells in the presence of LA or AA in vitro or in mice
fed the SDA diet was able to maintain the desirable N-6:N-3
ratio of c1 and 2. Therefore, for PCa intervention, it is rea-
sonable to consume excess nontoxic EPA and to facilitate
the production of antitumorigenic metabolites to counteract
the production of protumorigenic metabolites derived from
N-6 fatty acid pathways. In the present study, we used iso-
caloric fats, providing diets with 4.4 kcal/g. Short-term human
trials using 5.4 to 15 g/dayN-3 PUFA, to balance 13 g/dayN-6
[72–74], were harmless [75,76].
Consequently, 15-LO-1metabolizesEPA to15-HEPE [39],
a metabolite shown to have antitumorigenic properties,
whereas COX-2 metabolizes EPA to the anti-inflammatory
as well as antitumorigenic prostaglandin PGE3 [39–41].
Therefore, based on the substrates (i.e., dietary N-6 or N-3
in concert with the activities of 15-LO-1 and COXs), cells can
be predisposed to either a proliferative or an antiprolifera-
tive outcome. This effect seemed to be independent of per-
cent unsaturated or percent saturated fatty acids in the total
phospholipids, as observed in LAPC-4 cells treated with ei-
ther N-6 orN-3 fatty acids, because the cells are able to main-
tain the fluidity and functionality of proteins in the membrane.
Thus, the present study suggests that there is a link be-
tween PUFA lipid metabolism in the PCa and the fate of car-
cinogenesis, which is based on the balance between N-6
and N-3 PUFAs and their respective metabolic pathways.
The first and rate-limiting step in the shared N-3 and N-6
metabolic pathways, besides 15-LO-1, is also catalyzed by
D-6-desaturase (Figure 10). On one hand, the increased es-
timated activity of D-6-desaturase enzyme in the LAPC-4
cells treated with EPA alone or in the presence of LA or AA,
compared to untreated control, indicated an accumulation
of antiproliferative GLA and DGLA. However, a reduced es-
timated D-5-desaturase activity suggested that EPA could
inhibit D-5-desaturase enzyme activity, which eventually
limits the formation of DHA and also causes accumulation
of antitumorigenic DGLA and GLA. Interestingly, the esti-
mated activity of N-9 monounsaturated fatty acid pathway
enzyme D-9-desaturase decreased with LA and AA supple-
mented in the growth medium, but was not affected in the
presence of EPA, suggesting that EPA may favor the con-
version of stearic acid (18:0, N-9) to oleic acid (18:1, N-9),
which is otherwise inhibited by either LA and/or AA.
Based on the current study, we propose that, due to low
D-6 desaturase in cancer cells, their ability to convert either
N-6 LA to GLA or to convert N-3 a-linolenic acid (ALA) to
SDA, EPA, and DHA is severely limited. Cancer cells thus
have very low levels of GLA, DGLA, SDA, DHA, and EPA,
and, although ALA may accumulate, it is not converted
to SDA [77–84]; therefore, 15-LO-1 activity leading to pro-
proliferative actions probably through IGF-1 supports carci-
nogenesis [85]. Consequently, it is conceivable that, without
examining for 15-LO-1, studies evaluating a mixture of N-3
PUFAs, as found in fish oils in PCa intervention trials, can
yield confounding results (reviewed in Ref. [64]). Of note is
that an age-related decrease in D-6 desaturase activity cor-
responded with both low EPA and high ALA and LA con-
centrations in rats [78], suggesting the possibility that similar
effects are possible in aged humans, causing diseased pros-
tate tissues that are unable to convert sufficient quantities
of antiproliferative N-3 ALA to EPA. Importantly, US diets
provide excessive LA [14], and LA competes with ALA for
the desaturase and elongase enzymes, thus inhibiting the
conversion of ALA to EPA and DHA.
Epigenetic effects of high-fat PUFAs on gene expressions
of enzymes from the N-3 and N-6 pathways are unknown,
and possible mechanisms may involve DNA methylation of
promoters or the presence of transcriptional inhibitors—
studies that may require more research in the future. Using
LAPC-4 cells, an isocaloric low-fat diet slowed LAPC-4 tumor
growth, further corroborating a role for fats in PCa develop-
ment [8,9]. Although this observation and our current study
both suggest that a no-fat diet may be the most beneficial
diet to radical prostatectomy patients, compliance with a no-
fat diet would likely not be feasible in long-term clinical trials.
Combining a reduction of dietary N-6 fat with an intake of
essential N-3 fatty acids likely would be more attainable and,
thus, more beneficial.
PSA doubling time is the most powerful predictor of
progression, stratifying patients with biochemical failure into
high- and low-risk groups for clinical failure [86,87]. Our study
suggests that N-3 SDA caused a reduction in PSA doubling
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time that was exacerbated by N-6 LA. Although a clinical trial
will demonstrate its usefulness, the use of natural dietary N-3
supplementation after radical prostatectomy could poten-
tially be useful in improving biochemical progression-free
survival and local control in patients with a high risk of pro-
gression. In conclusion, due to the probable impact of N-3
and N-6 PUFAs on PCa development, our results strongly
support a dietary intervention role for N-3 PUFAs as adjunct
therapy in the prevention and treatment of PCa.
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